Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Mar 12 04:00PM ET
1.06
Dollar change
-0.01
Percentage change
-0.93
%
IndexRUT P/E- EPS (ttm)-1.65 Insider Own13.11% Shs Outstand92.38M Perf Week-7.83%
Market Cap98.58M Forward P/E- EPS next Y-2.28 Insider Trans0.06% Shs Float78.68M Perf Month-19.70%
Income-149.10M PEG- EPS next Q-0.45 Inst Own60.34% Short Float12.99% Perf Quarter-50.23%
Sales9.99M P/S9.87 EPS this Y-16.21% Inst Trans3.94% Short Ratio7.65 Perf Half Y-39.94%
Book/sh2.74 P/B0.39 EPS next Y-19.08% ROA-39.14% Short Interest10.22M Perf Year-85.71%
Cash/sh2.25 P/C0.47 EPS next 5Y-22.05% ROE-47.99% 52W Range1.01 - 7.24 Perf YTD-33.33%
Dividend Est.- P/FCF- EPS past 5Y-33.41% ROI-53.63% 52W High-85.36% Beta2.26
Dividend TTM- Quick Ratio7.16 Sales past 5Y42.68% Gross Margin60.71% 52W Low4.74% ATR (14)0.09
Dividend Ex-Date- Current Ratio7.16 EPS Y/Y TTM-14.04% Oper. Margin-1667.16% RSI (14)30.74 Volatility7.49% 7.45%
Employees147 Debt/Eq0.10 Sales Y/Y TTM-71.01% Profit Margin-1491.95% Recom1.40 Target Price13.80
Option/ShortYes / Yes LT Debt/Eq0.10 EPS Q/Q0.23% Payout- Rel Volume0.48 Prev Close1.07
Sales Surprise-1.39% EPS Surprise6.59% Sales Q/Q-41.62% EarningsMar 10 AMC Avg Volume1.34M Price1.06
SMA20-13.27% SMA50-24.49% SMA200-43.91% Trades Volume637,800 Change-0.93%
Date Action Analyst Rating Change Price Target Change
Jun-03-24Downgrade Evercore ISI Outperform → In-line $13 → $3
Nov-08-23Initiated Cantor Fitzgerald Neutral
Oct-31-23Initiated Evercore ISI Outperform $13
Jul-11-23Initiated Truist Buy $23
Feb-18-22Initiated RBC Capital Mkts Outperform $22
Dec-01-21Initiated Oppenheimer Outperform $36
Nov-30-21Initiated H.C. Wainwright Buy $28
Nov-15-21Upgrade Citigroup Neutral → Buy $27
Aug-17-21Initiated SVB Leerink Outperform $32
Aug-17-21Initiated Citigroup Neutral $27
Mar-10-25 05:15PM
04:05PM
Feb-18-25 04:05PM
05:45AM
Feb-07-25 05:45AM
05:45AM Loading…
Jan-31-25 05:45AM
Jan-24-25 05:45AM
Jan-17-25 05:45AM
Jan-14-25 05:45AM
Jan-12-25 07:05PM
Jan-07-25 04:00PM
Jan-02-25 08:00AM
Dec-30-24 03:01PM
Dec-16-24 09:55AM
Nov-20-24 04:00PM
06:05PM Loading…
Nov-06-24 06:05PM
04:05PM
Oct-31-24 03:53AM
Oct-17-24 03:06PM
Sep-25-24 09:00AM
Sep-03-24 08:00AM
Aug-26-24 04:00PM
Aug-12-24 08:00AM
Aug-06-24 06:50PM
04:05PM
10:00AM
Jul-17-24 07:45AM
Jul-09-24 08:00AM
Jun-02-24 07:00PM
May-30-24 04:01PM
04:00PM Loading…
May-12-24 04:00PM
May-09-24 05:23AM
May-07-24 10:55PM
05:25PM
04:05PM
May-01-24 04:05PM
Apr-27-24 06:00AM
Apr-24-24 10:00AM
Apr-15-24 09:00AM
Apr-04-24 04:00PM
Mar-14-24 12:00PM
Mar-13-24 03:32PM
Mar-12-24 12:37PM
Mar-11-24 04:05PM
Mar-05-24 04:30PM
Feb-26-24 01:14PM
06:45AM
Feb-23-24 11:25PM
Feb-15-24 04:05PM
Feb-12-24 08:30AM
Jan-15-24 08:45AM
Jan-07-24 11:00AM
Dec-13-23 07:26AM
05:20AM
Dec-12-23 04:02PM
Dec-08-23 12:00PM
Dec-06-23 09:55AM
Nov-20-23 09:55AM
Nov-07-23 04:00PM
Nov-06-23 08:00AM
Nov-01-23 04:05PM
Oct-20-23 05:00AM
Oct-18-23 08:00AM
Oct-11-23 06:00AM
Oct-10-23 05:40AM
Oct-05-23 10:07AM
Sep-27-23 08:30AM
08:00AM
Sep-23-23 08:45AM
Aug-29-23 04:00PM
Aug-24-23 05:58AM
Aug-15-23 04:08PM
03:08PM
Aug-08-23 05:15PM
04:00PM
Jul-28-23 08:30AM
Jul-22-23 09:45AM
Jul-21-23 10:00AM
Jul-20-23 11:35AM
Jul-19-23 09:30AM
Jul-17-23 05:03PM
Jul-14-23 11:27AM
Jul-13-23 11:15PM
04:03PM
04:01PM
04:01PM
09:30AM
Jul-12-23 09:40AM
Jul-11-23 09:55AM
Jul-07-23 08:14AM
Jul-06-23 11:03PM
01:56PM
11:54AM
10:43AM
08:00AM
Jun-15-23 12:53PM
May-31-23 04:00PM
May-16-23 11:25AM
May-09-23 05:15PM
04:00PM
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCCLUNG BARBARA GChief Legal OfficerFeb 21 '25Sale1.353,5644,811443,502Feb 21 08:19 PM
Khan Ruhi AhmadChief Business OfficerFeb 21 '25Sale1.353,5644,81166,936Feb 21 08:19 PM
Kanner StevenChief Scientific OfficerFeb 21 '25Sale1.353,5644,811431,556Feb 21 08:18 PM
Ryali SriramChief Financial OfficerJan 29 '25Buy1.4217,36024,65117,360Jan 30 04:02 PM
Last Close
Mar 12 04:00PM ET
2.76
Dollar change
0.00
Percentage change
0.00
%
CDXS Codexis Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-0.90 Insider Own2.74% Shs Outstand81.85M Perf Week1.10%
Market Cap228.63M Forward P/E- EPS next Y-0.56 Insider Trans374.12% Shs Float80.57M Perf Month-33.97%
Income-65.28M PEG- EPS next Q-0.24 Inst Own78.09% Short Float3.76% Perf Quarter-41.65%
Sales59.34M P/S3.85 EPS this Y17.04% Inst Trans2.13% Short Ratio3.73 Perf Half Y5.34%
Book/sh0.82 P/B3.38 EPS next Y23.81% ROA-45.72% Short Interest3.03M Perf Year-20.46%
Cash/sh0.89 P/C3.09 EPS next 5Y31.19% ROE-85.03% 52W Range2.47 - 6.08 Perf YTD-42.14%
Dividend Est.- P/FCF- EPS past 5Y-33.31% ROI-52.64% 52W High-54.61% Beta2.33
Dividend TTM- Quick Ratio4.10 Sales past 5Y4.02% Gross Margin64.39% 52W Low11.74% ATR (14)0.29
Dividend Ex-Date- Current Ratio4.18 EPS Y/Y TTM19.42% Oper. Margin-98.33% RSI (14)27.82 Volatility8.21% 8.03%
Employees188 Debt/Eq0.89 Sales Y/Y TTM-15.39% Profit Margin-109.99% Recom1.57 Target Price7.33
Option/ShortYes / Yes LT Debt/Eq0.85 EPS Q/Q-23.29% Payout- Rel Volume1.00 Prev Close2.76
Sales Surprise-21.71% EPS Surprise-258.13% Sales Q/Q-19.20% EarningsFeb 27 AMC Avg Volume812.60K Price2.76
SMA20-21.91% SMA50-34.61% SMA200-25.19% Trades Volume816,023 Change0.00%
Date Action Analyst Rating Change Price Target Change
Aug-19-24Downgrade The Benchmark Company Buy → Hold
Jun-03-24Resumed Jefferies Buy $5
May-30-24Initiated Cantor Fitzgerald Overweight $11
Feb-29-24Upgrade The Benchmark Company Hold → Buy
Nov-07-23Downgrade The Benchmark Company Buy → Hold
Aug-07-23Downgrade TD Cowen Outperform → Market Perform $21 → $4
May-09-23Downgrade H.C. Wainwright Buy → Neutral
Mar-31-22Resumed Piper Sandler Overweight $35
Mar-02-22Resumed Cowen Outperform
Apr-12-21Initiated Piper Sandler Overweight $32
Mar-07-25 04:05PM
Feb-28-25 11:02AM
02:36AM
Feb-27-25 06:35PM
05:36PM
04:05PM Loading…
04:05PM
Feb-18-25 04:05PM
Feb-14-25 05:15PM
Feb-13-25 04:05PM
Feb-06-25 04:05PM
Jan-16-25 04:05PM
Jan-10-25 04:05PM
Dec-06-24 04:05PM
Nov-19-24 04:05PM
Nov-14-24 04:05PM
04:05PM Loading…
Nov-12-24 04:05PM
04:05PM
Nov-11-24 04:05PM
Nov-08-24 04:05PM
Nov-04-24 04:05PM
Nov-01-24 09:01AM
Oct-31-24 05:30PM
04:23PM
04:05PM
Oct-24-24 04:05PM
Oct-22-24 04:05PM
Oct-15-24 07:10AM
Oct-14-24 07:05AM
Oct-10-24 04:05PM
Oct-09-24 05:56PM
04:05PM Loading…
Oct-02-24 04:05PM
Oct-01-24 07:05AM
Sep-26-24 01:01PM
Sep-24-24 01:03AM
Sep-20-24 02:25AM
Sep-06-24 04:05PM
Sep-03-24 04:05PM
Aug-20-24 04:05PM
Aug-16-24 04:05PM
Aug-15-24 04:05PM
Aug-08-24 05:55PM
04:51PM
04:05PM
Jul-18-24 04:05PM
Jul-10-24 01:30PM
Jul-03-24 07:37AM
Jul-02-24 09:27AM
Jul-01-24 04:05PM
Jun-12-24 05:48AM
May-22-24 04:25PM
May-20-24 04:05PM
May-14-24 06:00AM
May-03-24 11:14AM
06:47AM
04:01AM
May-02-24 06:06PM
05:34PM
04:05PM
Apr-18-24 04:05PM
Apr-11-24 07:05AM
Feb-29-24 10:40AM
07:08AM
Feb-28-24 06:50PM
06:01PM
04:59PM
04:05PM
Feb-26-24 04:05PM
08:05AM
Feb-20-24 08:05AM
Feb-14-24 04:05PM
Feb-13-24 04:05PM
Feb-01-24 04:05PM
Jan-08-24 07:03PM
Dec-27-23 08:30AM
Dec-14-23 06:45AM
Dec-13-23 04:06PM
04:05PM
Dec-11-23 07:05AM
Nov-29-23 02:46PM
Nov-28-23 04:05PM
Nov-14-23 04:05PM
Nov-03-23 09:14AM
08:58AM
Nov-02-23 06:24PM
05:04PM
04:05PM
Oct-31-23 04:05PM
Oct-27-23 03:35PM
Oct-26-23 04:05PM
Oct-19-23 04:05PM
Sep-29-23 07:05AM
Sep-18-23 04:05PM
Sep-16-23 03:02PM
Sep-13-23 01:02AM
Sep-12-23 04:05PM
Sep-11-23 08:21AM
Sep-08-23 04:44PM
Sep-07-23 04:05PM
Aug-24-23 09:29AM
Aug-08-23 06:00PM
Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Opaleye Management Inc.10% OwnerMar 06 '25Buy2.61100,000261,3509,065,000Mar 10 05:16 PM
Opaleye Management Inc.10% OwnerMar 04 '25Buy2.6455,000145,3988,955,000Mar 06 04:51 PM
Opaleye Management Inc.10% OwnerMar 05 '25Buy2.6910,00026,8758,965,000Mar 06 04:51 PM
Opaleye Management Inc.10% OwnerFeb 28 '25Buy2.99147,649441,1758,852,649Mar 04 04:05 PM
Opaleye Management Inc.10% OwnerMar 03 '25Buy2.8147,351133,1658,900,000Mar 04 04:05 PM
Opaleye Management Inc.10% OwnerFeb 10 '25Buy4.1822,50094,1498,677,500Feb 12 07:42 PM
Opaleye Management Inc.10% OwnerFeb 12 '25Buy4.0015,00059,9328,705,000Feb 12 07:42 PM
Opaleye Management Inc.10% OwnerFeb 11 '25Buy4.1112,50051,4008,690,000Feb 12 07:42 PM
Opaleye Management Inc.10% OwnerJan 31 '25Buy4.2945,000193,1858,655,000Jan 31 07:08 PM
Opaleye Management Inc.10% OwnerJan 30 '25Buy4.4920,00089,7828,610,000Jan 31 07:08 PM
Opaleye Management Inc.10% OwnerDec 30 '24Buy4.7035,000164,3928,580,000Jan 02 04:05 PM
Opaleye Management Inc.10% OwnerDec 31 '24Buy4.6610,00046,6038,590,000Jan 02 04:05 PM
Opaleye Management Inc.10% OwnerOct 25 '24Buy2.9125,00072,7208,545,000Oct 28 04:05 PM
Opaleye Management Inc.10% OwnerSep 24 '24Buy2.9480,000234,8568,515,000Sep 26 03:21 PM
Opaleye Management Inc.10% OwnerSep 25 '24Buy2.865,00014,2908,520,000Sep 26 03:21 PM
Opaleye Management Inc.10% OwnerSep 20 '24Buy3.011,055,0003,175,5508,390,000Sep 23 05:19 PM
Opaleye Management Inc.10% OwnerSep 23 '24Buy2.9445,000132,4848,435,000Sep 23 05:19 PM
Opaleye Management Inc.10% OwnerSep 18 '24Buy3.1661,000192,9927,380,000Sep 19 06:16 PM